Second primary cancer risks according to race and ethnicity among U.S. breast cancer survivors

Carolyn Brandt,Jacqueline B. Vo,Gretchen L. Gierach,Iona Cheng,Vanessa N. Torres,Wayne R. Lawrence,Lauren E. McCullough,Lene H. S. Veiga,Amy Berrington de González,Cody Ramin
DOI: https://doi.org/10.1002/ijc.34971
2024-05-01
International Journal of Cancer
Abstract:What's New? Breast cancer survivors are at increased risk of second cancer. Whether differences in second cancer risk exist between racial and ethnic groups, however, remains uncertain. Here, data from Surveillance, Epidemiology, and End Results (SEER) registries was investigated to elucidate second cancer risk for Black, Latina, White, and Asian American, Native Hawaiian, or other Pacific Islander (AANHPI) breast cancer survivors. Standardized incidence ratios show that second cancer risk is significantly elevated among AANHPI, Black, and Latina breast cancer survivors, particularly those with early‐onset and estrogen receptor‐negative disease. Racial and ethnic heterogeneity was observed for 16 out of 27 site‐specific second cancers. Breast cancer survivors have an increased risk of developing second primary cancers, yet risks by race and ethnicity have not been comprehensively described. We evaluated second primary cancer risks among 717,335 women diagnosed with first primary breast cancer (aged 20–84 years and survived ≥1‐year) in the SEER registries using standardized incidence ratios (SIRs; observed/expected). SIRs were estimated by race and ethnicity compared with the racial‐ and ethnic‐matched general population, and further stratified by clinical characteristics of the index breast cancer. Poisson regression was used to test for heterogeneity by race and ethnicity. SIRs for second primary cancer differed by race and ethnicity with the highest risks observed among non‐Hispanic/Latina Asian American, Native Hawaiian, or other Pacific Islander (AANHPI), non‐Hispanic/Latina Black (Black), and Hispanic/Latina (Latina) survivors and attenuated risk among non‐Hispanic/Latina White (White) survivors (SIRAANHPI = 1.49, 95% CI = 1.44–1.54; SIRBlack = 1.41, 95% CI = 1.37–1.45; SIRLatina = 1.45, 95% CI = 1.41–1.49; SIRWhite = 1.09, 95% CI = 1.08–1.10; p‐heterogeneity
oncology
What problem does this paper attempt to address?